Liability related to sale of future royalties, net as of December 31, 2024

$

542,212

Royalty payments to Royalty Pharma

(24,894

)

Interest expense related to sale of future royalties

37,165

Amortization of issuance costs related to sale of future royalties

305

Liability related to sale of future royalties, net as of June 30, 2025

$

554,788

Less: Current portion (1)

(13,583

)

Liability related to sale of future royalties, net as of June 30, 2025 – Non-current

$

541,205